These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 12519867)

  • 1. Effects of the 11 beta-hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes.
    Andrews RC; Rooyackers O; Walker BR
    J Clin Endocrinol Metab; 2003 Jan; 88(1):285-91. PubMed ID: 12519867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is 11beta-hydroxysteroid dehydrogenase type 1 a therapeutic target? Effects of carbenoxolone in lean and obese Zucker rats.
    Livingstone DE; Walker BR
    J Pharmacol Exp Ther; 2003 Apr; 305(1):167-72. PubMed ID: 12649365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of 11β-hydroxysteroid dehydrogenase 1 by carbenoxolone affects glucose homeostasis and obesity in db/db mice.
    Dhanesha N; Joharapurkar A; Shah G; Kshirsagar S; Dhote V; Sharma A; Jain M
    Clin Exp Pharmacol Physiol; 2012 Jan; 39(1):69-77. PubMed ID: 22060140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIS-388, a novel orally active and long-acting 11β-hydroxysteroid dehydrogenase type 1 inhibitor, ameliorates insulin sensitivity and glucose intolerance in diet-induced obesity and nongenetic type 2 diabetic murine models.
    Okazaki S; Takahashi T; Iwamura T; Nakaki J; Sekiya Y; Yagi M; Kumagai H; Sato M; Sakami S; Nitta A; Kawai K; Kainoh M
    J Pharmacol Exp Ther; 2014 Oct; 351(1):181-9. PubMed ID: 25100752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carbenoxolone increases hepatic insulin sensitivity in man: a novel role for 11-oxosteroid reductase in enhancing glucocorticoid receptor activation.
    Walker BR; Connacher AA; Lindsay RM; Webb DJ; Edwards CR
    J Clin Endocrinol Metab; 1995 Nov; 80(11):3155-9. PubMed ID: 7593419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of peroxisome proliferator-activated receptor-alpha and -gamma agonists on 11beta-hydroxysteroid dehydrogenase type 1 in subcutaneous adipose tissue in men.
    Wake DJ; Stimson RH; Tan GD; Homer NZ; Andrew R; Karpe F; Walker BR
    J Clin Endocrinol Metab; 2007 May; 92(5):1848-56. PubMed ID: 17327378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased in vivo regeneration of cortisol in adipose tissue in human obesity and effects of the 11beta-hydroxysteroid dehydrogenase type 1 inhibitor carbenoxolone.
    Sandeep TC; Andrew R; Homer NZ; Andrews RC; Smith K; Walker BR
    Diabetes; 2005 Mar; 54(3):872-9. PubMed ID: 15734867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-dose growth hormone inhibits 11 beta-hydroxysteroid dehydrogenase type 1 but has no effect upon fat mass in patients with simple obesity.
    Tomlinson JW; Crabtree N; Clark PM; Holder G; Toogood AA; Shackleton CH; Stewart PM
    J Clin Endocrinol Metab; 2003 May; 88(5):2113-8. PubMed ID: 12727963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased expression of 11beta-hydroxysteroid dehydrogenase type 1 in type 2 diabetic myotubes.
    Abdallah BM; Beck-Nielsen H; Gaster M
    Eur J Clin Invest; 2005 Oct; 35(10):627-34. PubMed ID: 16178882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 lowers intraocular pressure in patients with ocular hypertension.
    Rauz S; Cheung CM; Wood PJ; Coca-Prados M; Walker EA; Murray PI; Stewart PM
    QJM; 2003 Jul; 96(7):481-90. PubMed ID: 12881590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute in vivo regulation of 11beta-hydroxysteroid dehydrogenase type 1 activity by insulin and intralipid infusions in humans.
    Wake DJ; Homer NZ; Andrew R; Walker BR
    J Clin Endocrinol Metab; 2006 Nov; 91(11):4682-8. PubMed ID: 16954164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinguishing the activities of 11beta-hydroxysteroid dehydrogenases in vivo using isotopically labeled cortisol.
    Andrew R; Smith K; Jones GC; Walker BR
    J Clin Endocrinol Metab; 2002 Jan; 87(1):277-85. PubMed ID: 11788660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains.
    Alberts P; Nilsson C; Selen G; Engblom LO; Edling NH; Norling S; Klingström G; Larsson C; Forsgren M; Ashkzari M; Nilsson CE; Fiedler M; Bergqvist E; Ohman B; Björkstrand E; Abrahmsen LB
    Endocrinology; 2003 Nov; 144(11):4755-62. PubMed ID: 12960099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo activity of 11beta-hydroxysteroid dehydrogenase type 1 and free fatty acid-induced insulin resistance.
    Mai K; Kullmann V; Bobbert T; Maser-Gluth C; Möhlig M; Bähr V; Pfeiffer AF; Spranger J; Diederich S
    Clin Endocrinol (Oxf); 2005 Oct; 63(4):442-9. PubMed ID: 16181237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of relationship between 11beta-hydroxysteroid dehydrogenase setpoint and insulin sensitivity in the basal state and after 24h of insulin infusion in healthy subjects and type 2 diabetic patients.
    Kerstens MN; Riemens SC; Sluiter WJ; Pratt JJ; Wolthers BG; Dullaart RP
    Clin Endocrinol (Oxf); 2000 Apr; 52(4):403-11. PubMed ID: 10762282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carbenoxolone treatment attenuates symptoms of metabolic syndrome and atherogenesis in obese, hyperlipidemic mice.
    Nuotio-Antar AM; Hachey DL; Hasty AH
    Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1517-28. PubMed ID: 17878220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sub-chronic administration of the 11beta-HSD1 inhibitor, carbenoxolone, improves glucose tolerance and insulin sensitivity in mice with diet-induced obesity.
    Taylor A; Irwin N; McKillop AM; Flatt PR; Gault VA
    Biol Chem; 2008 Apr; 389(4):441-5. PubMed ID: 18225986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of 11beta-hydroxysteroid dehydrogenase 1 and 2 in subcutaneous adipose tissue of lean and obese women with and without polycystic ovary syndrome.
    Svendsen PF; Madsbad S; Nilas L; Paulsen SK; Pedersen SB
    Int J Obes (Lond); 2009 Nov; 33(11):1249-56. PubMed ID: 19704410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of carbenoxolone on the plasma renin activity and hypothalamic-pituitary-adrenal axis in congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
    Irony I; Cutler GB
    Clin Endocrinol (Oxf); 1999 Sep; 51(3):285-91. PubMed ID: 10469007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered activity of 11beta-hydroxysteroid dehydrogenase types 1 and 2 in skeletal muscle confers metabolic protection in subjects with type 2 diabetes.
    Jang C; Obeyesekere VR; Dilley RJ; Krozowski Z; Inder WJ; Alford FP
    J Clin Endocrinol Metab; 2007 Aug; 92(8):3314-20. PubMed ID: 17519316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.